PD-1阻断剂所致皮肤不良反应分析及文献回顾  

PD-1 blockade therapy induced skin irAEs:cases report and literature review

作　　者：孙靓 韩丹[1] 胡菊丽 刘文丽[1] 周艳[1] 梁艳[1] 穆欣[1] 牟宽厚[1] SUN Liang;HAN Dan;HU Juli;LIU Wenli;ZHOU Yan;LIANG Yan;MU Xin;MU Kuanhou(Department of Dermatology,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China;Department of Dermatology,Xunyi County Hospital of Shaanxi Province,Xunyi 711300,China)

机构地区：[1]西安交通大学第一附属医院皮肤科,陕西西安710061 [2]陕西省咸阳市旬邑县医院皮肤科,陕西旬邑711300

出　　处：《中国麻风皮肤病杂志》2022年第3期153-157,共5页China Journal of Leprosy and Skin Diseases

基　　金：国家自然科学基金(编号:81972935)。

摘　　要：抗程序细胞死亡蛋白1及配体阻断剂为代表的免疫治疗在肿瘤治疗中取得了突破性的进展,皮肤不良反应是最常见的免疫相关不良反应(irAEs)。本文报道临床中诊治的一组免疫相关不良反应,共4例,分别为湿疹、多形红斑、TEN、嗜酸细胞增多性皮炎,并回顾分析在Pubmed数据库检索2015年至今发表的PD-1/PD-L1免疫治疗导致皮肤不良反应的病例报道,包括患者年龄、性别、致皮肤irAEs的药物、皮肤irAEs类型等。以期提高对肿瘤免疫治疗过程中皮肤不良反应的关注,及时救治危及生命的皮肤不良反应,帮助改善肿瘤患者生存质量和预后。PD-1/PD-L1 blockade therapy is a representative immunotherapy that shows a major breakthrough in cancer therapy and dermatologic reactions are the most prevalent immune-related adverse events(irAEs).We reported 4 cases of different skin irAEs,including eczema,erythema multiforme,TEN,eosinophilic dermatitis.And the studies of dermatologic reactions induced by PD-1/PD-L1 blockade from Pubmed since 2015 were respectively analyzed,including sex,age,drug and lesion type,etc.In order to improve the attention of irAEs manifested as skin disease,to timely treat the patient with life-threatening adverse reactions,and to help improve the quality of life and prognosis of tumor patients.

关 键 词：肿瘤免疫治疗 免疫检查点抑制剂 皮肤免疫相关不良反应 

分 类 号：R730.51[医药卫生—肿瘤]